ClinicalTrials.gg
CompletedNCT01512745Updated Oct 17, 2016Results posted

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

A Phase 3 interventional study of apatinib and placebo in Advanced or Metastatic Gastric Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 2 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-17.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
267
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing apatinib in Stomach Neoplasms — 14 open to participants now, 15 under way, 4 of them phase 3. apatinib · Stomach Neoplasms.

Enrollment
6th of 57
267 · median 47
Started
2011
the only one that year
Phase 3
9 of 57
4 open now
Registered
2nd of 57
by date
Lead sponsor
5 of 57
Jiangsu HengRui Medicine Co., Ltd.

Among the 57 studies testing apatinib in Stomach Neoplasms, this one is the 6th largest by enrollment, is the only one that started in 2011, is one of 9 in phase 3, and was the 2nd registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

14 of the 57 studies testing apatinib in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apatinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing apatinib in Stomach Neoplasms, or all of them as a file.
02

Study summary

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival or overall survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.

03

Conditions studied

  • Advanced or Metastatic Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 and ≤ 70 years of age
  • Histological confirmed advanced or adenocarcinoma of the stomach
  • Have failed for at least 2
  • of at least 12 weeks.
  • Performance Status of 0 or 1 within 1 week before randomization.
  • At least one beyond stomach (larger than 10 mm in diameter by spiral CT scan)
  • Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
  • More than 4 weeks for operation or radiotherapy
  • More than 4 weeks for cytotoxic agents or growth inhibitors
  • Adequate hepatic, renal, heart, and hematologic functions (HB ≥ 90g/L, > 80 ×10 E+9/L, neutrophil > 1.5 × 10 E+9/L, serum creatinine ≤ 1× (ULN), \< 1.25× ULN, and serum transaminase ≤ 2.5× ULN).

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • History of other except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg).
  • Any factors that influence the usage of oral administration; Evidence of Central Nerves System(CNS)
  • Intercurrence with one of the following: coronary artery disease, arrhythmia ,heart failure and proteinuria ≥ (+)
  • International Normalize Ratio () > 1.5 and activated partial thromboplastin time(APPT) > 1.5 ×
  • Abuse of alcohol or drugs
  • Certain possibility of gastric or intestine hemorrhage
  • Less than 4 weeks from the last clinical trial
  • Prior VEGFR inhibitor treatment
  • Disability of serious uncontrolled intercurrence infection Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary function damaged seriously etc.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
267 participants (actual)

Study arms

  • Experimental
    apatinib

    Drug: apatinib

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

  • Drugplacebo

    placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

06

What researchers measure

Primary outcomes

  1. Progression Free Survival(PFS)

    Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

    Time frame: 30 months

  2. Overall Survival(OS)

    Overall Survival of the Participants

    Time frame: 30 months

Secondary outcomes

  1. Disease Control Rate(DCR)

    Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.

    Time frame: 30 months

  2. Objective Response Rate(ORR)

    Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)

    Time frame: 30 months

  3. Percentage of Participants With Adverse Events

    Time frame: 30 months

07

Results

Posted Jun 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneApatinibPlacebo
Started17691
Completed13671
Not completed4020
Withdrew: Adverse event223
Withdrew: Death913
Withdrew: Withdrawal by subject22
Withdrew: Lost to follow-up40
Withdrew: Lack of efficacy22
Withdrew: Protocol violation10

Outcome measures

PrimaryProgression Free Survival(PFS)

Progression free survival of All the Evaluable Participants.Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of diameters of target lesions, in addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

Time frame:
30 months
Reported as:
Median · month
Progression Free Survival(PFS)
monthApatinibPlacebo
Progression Free Survival(PFS)2.6 (2.0 to 2.9)1.8 (1.4 to 1.9)
PrimaryOverall Survival(OS)

Overall Survival of the Participants

Time frame:
30 months
Reported as:
Median · month
Overall Survival(OS)
monthApatinibPlacebo
Overall Survival(OS)6.5 (4.8 to 7.6)4.7 (3.6 to 5.4)
SecondaryDisease Control Rate(DCR)

Disease control is defined as the proportion of patients who had a best response rating of complete response, partial response, or stable disease, and lasted at least 4 weeks.

Time frame:
30 months
Reported as:
Number · percentage of participants
Disease Control Rate(DCR)
percentage of participantsApatinibPlacebo
Disease Control Rate(DCR)42.058.79
SecondaryObjective Response Rate(ORR)

Objective Response Rate is defined as the proportion of patients with complete response(CR) or partial response(PR)

Time frame:
30 months
Reported as:
Number · percentage of participants
Objective Response Rate(ORR)
percentage of participantsApatinibPlacebo
Objective Response Rate(ORR)2.840.00
SecondaryPercentage of Participants With Adverse Events
Time frame:
30 months
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events
percentage of participantsApatinibPlacebo
Percentage of Participants With Adverse Events98.3090.11

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apatinib—6/176 (3.4%)173/176 (98.3%)
Placebo—6/91 (6.6%)82/91 (90.1%)
Most frequent serious events
Most frequent serious events
EventApatinibPlacebo
Gastrointestinal bleedingGastrointestinal disorders5/1765/91
Abdominal painGastrointestinal disorders1/1761/91
Most frequent other events
Showing 10 of 18
Most frequent other events
EventApatinibPlacebo
proteinuriaRenal and urinary disorders84/17615/91
leukopeniaBlood and lymphatic system disorders71/1768/91
neutropeniaBlood and lymphatic system disorders66/1769/91
hypertensionVascular disorders62/1765/91
hand-foot syndromeSkin and subcutaneous tissue disorders49/1762/91
elevated transaminaseHepatobiliary disorders49/17620/91
anemiaBlood and lymphatic system disorders44/17622/91
thrombocytopeniaBlood and lymphatic system disorders44/1766/91
hyperbilirubinemiaHepatobiliary disorders43/17613/91
bleedingBlood and lymphatic system disorders35/17622/91

Baseline characteristics

5 participants in the apatinib group and 1 in the placebo group withdrew from the study before receiving the assigned treatments.As a result,267 randomly assigned participants were included in Full Analysis Set (FAS),with 176 assigned to the apatinib group and 91 assigned to the placeo group.

Age, Continuous
Age, Continuous(years)ApatinibPlaceboTotal
Mean55.01 ± 9.9256.08 ± 9.7455.37 ± 9.81
Sex: Female, Male
Sex: Female, Male(Participants)ApatinibPlaceboTotal
Female442266
Male13269201
08

Study locations

2 sites
  • The 81 Hosiptal of PLA
    Nanjing, Jiangsu, China
  • Fudan University cancer hospital
    Shanghai, Shanghai, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2012
First posted
Jan 19, 2012
Start
Jan 2011
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Jun 15, 2016
Last update
Oct 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01512745
Collaborators
Fudan University, The 81 Hospital of PLA
Responsible party
Sponsor
First posted
Jan 19, 2012
Start date
Jan 2011
Primary completion
May 2013
Completion
May 2013
Results posted
Jun 15, 2016
Last update
Oct 17, 2016

Study contacts

Jin Li, MD, PHD
principal investigator · Fudan University
Shukui Qin, MD
principal investigator · The 81 Hospital of PLA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apatinib

Start the discussion